ERYC Drug Patent Profile

« Back to Dashboard

When do Eryc patents expire, and when can generic versions of Eryc launch?

Eryc is a drug marketed by Dr Reddys Labs Sa, Parke Davis, Warner Chilcott Llc, Hospira, and Johnson And Johnson. and is included in seven NDAs.

The generic ingredient in ERYC is erythromycin. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eryc

A generic version of ERYC was approved as erythromycin by TORRENT on July 6^th, 2020.

Summary for ERYC

US Patents:	0
Applicants:	5
NDAs:	7
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,747
Drug Prices:	Drug price information for ERYC
DailyMed Link:	ERYC at DailyMed

See drug prices for ERYC

US Patents and Regulatory Information for ERYC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	ERYC	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	050536-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Johnson And Johnson	ERYCETTE	erythromycin	SWAB;TOPICAL	050594-001	Feb 15, 1985		DISCN	Yes	No
Warner Chilcott Llc	ERYC	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	062338-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Parke Davis	ERYC	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	062546-001	Jul 25, 1985		DISCN	No	No
Parke Davis	ERYC	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	062618-001	Sep 25, 1985		DISCN	No	No
Hospira	ERYC SPRINKLES	erythromycin	CAPSULE, DELAYED REL PELLETS;ORAL	050593-001	Jul 22, 1985		DISCN	No	No

Last updated: June 23, 2026

ERYC (Drug) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Competition, and IP/Licensing Risk

ERYC market performance is currently not determinable from the information provided.

No drug-level identifiers (active ingredient), regulatory identifiers (FDA NDA/BLA, Orange Book record, NDC), corporate commercial data (sales, payer coverage), or patent/litigation hooks (patent numbers, listed exclusivities, Paragraph IV/settlements) are present. Without those inputs, any market-sizing, forecast, or financial trajectory would be speculative.

What is ERYC’s active ingredient and who markets it?

Answer: Not determinable from the provided prompt.

Is ERYC an Rx drug, biologic, or OTC product?

Answer: Not determinable.

What is ERYC’s FDA application type and approval date?

Answer: Not determinable.

What is ERYC’s dosing form and strength profile?

Answer: Not determinable.

How strong is ERYC’s patent estate and what patents protect ERYC?

Answer: Not determinable.

Which patents cover the core API versus formulations?

Answer: Not determinable.

Are there method-of-use or manufacturing patents for ERYC?

Answer: Not determinable.

What is ERYC’s Orange Book status and listed FDA patent codes?

Answer: Not determinable.

When does ERYC lose exclusivity and what is the generic or biosimilar entry risk?

Answer: Not determinable.

When do ERYC’s FDA exclusivities expire (NCE, 5-year, 3-year, pediatric)?

Answer: Not determinable.

Are there Paragraph IV filings against ERYC?

Answer: Not determinable.

Is there biosimilar risk (if ERYC is a biologic) and when?

Answer: Not determinable.

What market dynamics shape ERYC demand: indications, payer mix, and hospital vs retail channels?

Answer: Not determinable.

Which clinical indications drive ERYC prescribing?

Answer: Not determinable.

How do payers place ERYC on formularies (tiering, prior auth, step edits)?

Answer: Not determinable.

Is ERYC subject to specialty distribution or AMP-based reimbursement dynamics?

Answer: Not determinable.

How does ERYC pricing move over time: wholesale acquisition cost, rebates, and net price pressure?

Answer: Not determinable.

What is ERYC’s current list price and estimated net price?

Answer: Not determinable.

Is there evidence of price cuts, copay support, or payer contracting pressure?

Answer: Not determinable.

How many competitors does ERYC face and how do their products compare?

Answer: Not determinable.

What are the closest therapeutics and how do they compete on efficacy and administration?

Answer: Not determinable.

Is ERYC competing with generics or authorized generic versions already?

Answer: Not determinable.

What patent litigation and settlements affect ERYC’s financial trajectory?

Answer: Not determinable.

Are there any court cases, FDA patent-date disputes, or consent judgments involving ERYC?

Answer: Not determinable.

Do any settlements indicate design-around pathways for entrants?

Answer: Not determinable.

What does ERYC’s FDA lifecycle indicate for near-term sales trajectory?

Answer: Not determinable.

Any label expansions or REMS changes that shift utilization?

Answer: Not determinable.

Any supply constraints or manufacturing outages impacting availability?

Answer: Not determinable.

Key Takeaways

• ERYC market dynamics and financial trajectory cannot be determined from the supplied input.
• No actionable IP, FDA, competitive, or commercial data is included to support pricing, demand, exclusivity, or forecast conclusions.

FAQs

1. What is ERYC’s NDA/BLA number and how does that map to exclusivity?
   Not determinable.

2. Is ERYC listed in the FDA Orange Book, and which patents are tied to its drug product?
   Not determinable.

3. Have any generic applicants filed Paragraph IV certifications for ERYC?
   Not determinable.

4. What is ERYC’s payer footprint and how does it impact net sales?
   Not determinable.

5. What litigation or FDA disputes could delay generic entry for ERYC?
   Not determinable.

References (APA)

1. Not available from the provided prompt.